

REMARKS

Claim 3 has been amended better to point out applicants' invention; the claim has been changed to state that "the dextran is attached to the carrier through a component resulting from the irradiation of the 3-trifluoromethyl-3-(m-isocyanophenyl)-diazimin (TRIMID)-modified aminodextran," rather than through the modified aminodextran itself. The Examiner is referred to the specification at page 5, lines 20 to 25 and Fig. 1 which provide support for the change.

Favorable treatment of claims 3 and 6 to 15 is earnestly solicited.


The Examiner is requested to telephone the undersigned if additional changes are required in the case prior to allowance.

Respectfully submitted,

PARKHURST & WENDEL, L.L.P.



Charles A. Wendel  
Registration No. 24,453



Date

CAW/ch  
Attorney Docket No.: CSEM:065  
PARKHURST & WENDEL, L.L.P.  
1421 Prince Street  
Suite 210  
Alexandria, Virginia 22314-2805  
Telephone: (703) 739-0220